About Asher Biotherapeutics
Asher Biotherapeutics is a company based in San Francisco (United States) founded in 2019 by Andy Yeung and Ivana Djuretic. Asher Biotherapeutics has raised $218.49 million across 4 funding rounds from investors including ARE, Astrazeneca and Marshall Wace. Asher Biotherapeutics offers products and services including Etakafusp alfa, AB821, and AB359. Asher Biotherapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Moderna, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter San Francisco, United States
- Founders Andy Yeung, Ivana Djuretic
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Asher Biotherapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$218.49 M (USD)
in 4 rounds
-
Latest Funding Round
$55 M (USD), Series C
Apr 03, 2024
-
Investors
ARE
& 13 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Asher Biotherapeutics
Asher Biotherapeutics offers a comprehensive portfolio of products and services, including Etakafusp alfa, AB821, and AB359.
Cis-targeted IL-2 for activating CD8+ T cells in cancer therapy.
Cis-targeted therapy for augmenting cell therapies in oncology.
Cis-targeted cytokine for enhancing immune cell responses.
People of Asher Biotherapeutics
Unlock access to complete
Unlock access to complete
Leadership Team
11 people
Scientific Team
7 people
Founder Team
1 people
Consultant Team
1 people
Unlock access to complete
Funding Insights of Asher Biotherapeutics
Asher Biotherapeutics has successfully raised a total of $218.49M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $55 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Asher Biotherapeutics
Asher Biotherapeutics has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include ARE, Astrazeneca and Marshall Wace.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Venture capital funding is provided to early-stage life science companies.
|
Locked | Locked | Locked | |
|
Biotech startups are funded by this venture capital firm.
|
Locked | Locked | Locked |
Investor details for Asher Biotherapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Asher Biotherapeutics
Investment portfolio details for Asher Biotherapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Asher Biotherapeutics
Detailed financials for Asher Biotherapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Asher Biotherapeutics Comparisons
Peer comparison for Asher Biotherapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Asher Biotherapeutics
Asher Biotherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Moderna, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Asher Biotherapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Asher Biotherapeutics
Complete news archive for Asher Biotherapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Asher Biotherapeutics
Asher Biotherapeutics was founded in 2019.
Asher Biotherapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Craig Gibbs is the current CEO of Asher Biotherapeutics.
Asher Biotherapeutics is a funded company, having raised a total of $218.49M across 4 funding rounds to date.
Asher Biotherapeutics was founded in 2019 in San Francisco, United States, within the biotechnology sector. CIS-targeted immunotherapies are developed to activate specific immune cell types for treating cancer and autoimmune diseases. The pipeline features AB248, aimed at cancer and infectious diseases, alongside treg cis-targeted IL-2 for autoimmune conditions. Operations focus on improving therapeutic outcomes through immune modulation.
Asher Biotherapeutics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Asher Biotherapeutics offers Etakafusp alfa, AB821, and AB359.
Asher Biotherapeutics has 14 investors. Key investors include ARE, Astrazeneca, Marshall Wace, Janus Henderson Investors, and RA Capital.